All In Biotech

NDA 019357 · Qol Medcl

Ethamolin

Ethanolamine Oleate · Injection

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Feb 7, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 22, 1988

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

1 Phase 3, 0 recruiting

FAERS reports

18

18 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 10, 2025.

INDICATIONS AND USAGE ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • ETHAMOLIN · ETHANOLAMINE OLEATE 50MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethanolamine Oleate" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • oesophageal varices haemorrhage5
  • portal vein thrombosis3
  • product use in unapproved indication3
  • off label use2
  • abdominal pain1
  • abdominal pain upper1
  • anaemia1
  • arterial haemorrhage1
  • ascites1
  • cataract1
  • disseminated intravascular coagulation1
  • dry eye1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20138
20151
20171
20183
20191
20202
20221
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Ethamolin (Ethanolamine Oleate) · HCPCS J1430

2024 spending

$14K

Beneficiaries

16

26 claims

Per beneficiary

$844

2024 ASP limit $484.76 per unit

View as table
YearSpending
2020$20,041
2021$39,529
2022$28,798
2023$21,042
2024$13,504

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 68 on PubMed

Sponsor: Qol Medcl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.